Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.

Kummar S, Gutierrez ME, Anderson LW, Klecker RW Jr, Chen A, Murgo AJ, Doroshow JH, Collins JM.

Cancer Chemother Pharmacol. 2013 Oct;72(4):917-23. doi: 10.1007/s00280-013-2244-4. Epub 2013 Aug 3.

PMID:
23912694
[PubMed - indexed for MEDLINE]
2.

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.

Hollebecque A, Deutsch E, Massard C, Gomez-Roca C, Bahleda R, Ribrag V, Bourgier C, Lazar V, Lacroix L, Gazzah A, Varga A, de Baere T, Beier F, Kroesser S, Trang K, Zenke FT, Klevesath M, Soria JC.

Invest New Drugs. 2013 Dec;31(6):1530-8.

PMID:
24077982
[PubMed - indexed for MEDLINE]
3.

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J.

Clin Cancer Res. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. Epub 2010 Aug 30.

PMID:
20805299
[PubMed - indexed for MEDLINE]
Free Article
4.

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A.

Cancer Chemother Pharmacol. 2008 Jun;62(1):97-109. Epub 2007 Sep 6.

PMID:
17805538
[PubMed - indexed for MEDLINE]
5.

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.

Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ.

Clin Cancer Res. 2012 Jun 15;18(12):3396-406. doi: 10.1158/1078-0432.CCR-11-2703. Epub 2012 May 25.

PMID:
22634319
[PubMed - indexed for MEDLINE]
Free Article
6.

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.

Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, Goodwin A, Kromplewski M, Jayaprakash N, Marotti M, Brown KH, Wenrich B, Adamson PC, Widemann BC, Balis FM.

J Clin Oncol. 2010 Dec 10;28(35):5174-81. doi: 10.1200/JCO.2010.30.9674. Epub 2010 Nov 8.

PMID:
21060028
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL.

J Clin Oncol. 2012 May 1;30(13):1527-33. doi: 10.1200/JCO.2011.38.9346. Epub 2012 Mar 26.

PMID:
22454420
[PubMed - indexed for MEDLINE]
Free Article
8.

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM.

J Clin Oncol. 2002 Sep 15;20(18):3815-25.

PMID:
12228201
[PubMed - indexed for MEDLINE]
Free Article
9.

Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat.

Ames MM, Mathiesen DA, Reid JM.

Invest New Drugs. 1991 Aug;9(3):219-25.

PMID:
1783521
[PubMed - indexed for MEDLINE]
10.

Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.

Supko JG, Eder JP Jr, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.

Clin Cancer Res. 2003 Nov 1;9(14):5178-86.

PMID:
14613997
[PubMed - indexed for MEDLINE]
Free Article
11.

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.

Gomez HL, Philco M, Pimentel P, Kiyan M, Monsalvo ML, Conlan MG, Saikali KG, Chen MM, Seroogy JJ, Wolff AA, Escandon RD.

Anticancer Drugs. 2012 Mar;23(3):335-41. doi: 10.1097/CAD.0b013e32834e74d6.

PMID:
22123335
[PubMed - indexed for MEDLINE]
12.

Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.

Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC.

Clin Cancer Res. 2010 Apr 1;16(7):2167-75. doi: 10.1158/1078-0432.CCR-09-2236. Epub 2010 Mar 16.

PMID:
20233886
[PubMed - indexed for MEDLINE]
Free Article
13.

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.

Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y.

Cancer Chemother Pharmacol. 2012 Mar;69(3):835-43. doi: 10.1007/s00280-011-1779-5. Epub 2011 Nov 22.

PMID:
22105720
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.

Sewak S, Sorich J, O'Leary J.

Anticancer Drugs. 2006 Jun;17(5):571-9.

PMID:
16702815
[PubMed - indexed for MEDLINE]
15.

Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.

Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G.

Invest New Drugs. 2012 Jun;30(3):1039-45. doi: 10.1007/s10637-010-9629-6. Epub 2011 Jan 12.

PMID:
21225315
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.

Posey JA 3rd, Saif MW, Carlisle R, Goetz A, Rizzo J, Stevenson S, Rudoltz MS, Kwiatek J, Simmons P, Rowinsky EK, Takimoto CH, Tolcher AW.

Clin Cancer Res. 2005 Nov 1;11(21):7866-71.

PMID:
16278410
[PubMed - indexed for MEDLINE]
Free Article
17.

Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.

Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, Berger MS, Viallet J, Marshall JL.

Clin Cancer Res. 2010 Aug 1;16(15):4038-45. doi: 10.1158/1078-0432.CCR-10-0822. Epub 2010 Jun 10.

PMID:
20538761
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.

Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M.

Ann Oncol. 2003 Jun;14(6):922-30.

PMID:
12796031
[PubMed - indexed for MEDLINE]
Free Article
19.

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.

Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L.

Clin Cancer Res. 2010 Jan 15;16(2):699-710. doi: 10.1158/1078-0432.CCR-09-1365. Epub 2010 Jan 12.

PMID:
20068101
[PubMed - indexed for MEDLINE]
Free Article
20.

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI.

Ann Oncol. 2005 Aug;16(8):1391-7. Epub 2005 May 19.

PMID:
15905307
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk